FY2028 Earnings Estimate for Disc Medicine Issued By Wedbush

Disc Medicine, Inc. (NASDAQ:IRON - Free Report) - Research analysts at Wedbush lifted their FY2028 EPS estimates for shares of Disc Medicine in a note issued to investors on Wednesday, October 22nd. Wedbush analyst D. Nierengarten now anticipates that the company will earn $1.79 per share for the year, up from their previous forecast of $1.64. Wedbush has a "Outperform" rating and a $110.00 price objective on the stock. The consensus estimate for Disc Medicine's current full-year earnings is ($4.07) per share.

Several other research firms have also recently issued reports on IRON. Morgan Stanley raised their target price on Disc Medicine from $85.00 to $90.00 and gave the stock an "overweight" rating in a research note on Monday, August 18th. Weiss Ratings reissued a "sell (d-)" rating on shares of Disc Medicine in a research note on Wednesday, October 8th. Truist Financial initiated coverage on shares of Disc Medicine in a report on Monday, July 21st. They issued a "buy" rating and a $86.00 price objective for the company. National Bankshares set a $153.00 price objective on shares of Disc Medicine in a report on Friday, October 17th. Finally, HC Wainwright restated a "buy" rating and issued a $118.00 price objective on shares of Disc Medicine in a report on Thursday, July 3rd. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $110.70.

Disc Medicine Stock Down 4.0%

NASDAQ IRON opened at $83.69 on Friday. The company has a debt-to-equity ratio of 0.05, a current ratio of 32.11 and a quick ratio of 32.11. The stock has a market capitalization of $2.91 billion, a PE ratio of -18.72 and a beta of 0.80. Disc Medicine has a 1 year low of $30.82 and a 1 year high of $95.95. The business's 50-day moving average is $65.78 and its 200 day moving average is $55.89.

Disc Medicine (NASDAQ:IRON - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The company reported ($1.58) earnings per share for the quarter, missing the consensus estimate of ($1.17) by ($0.41).

Insider Buying and Selling at Disc Medicine

In other news, Director Kevin Bitterman sold 70,000 shares of the company's stock in a transaction dated Friday, October 17th. The shares were sold at an average price of $88.91, for a total value of $6,223,700.00. Following the sale, the director directly owned 385,549 shares of the company's stock, valued at $34,279,161.59. This represents a 15.37% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Over the last quarter, insiders have sold 226,933 shares of company stock valued at $17,005,801. 3.64% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Disc Medicine

A number of institutional investors and hedge funds have recently made changes to their positions in the business. RA Capital Management L.P. purchased a new position in Disc Medicine during the first quarter valued at $78,288,000. Siren L.L.C. purchased a new position in Disc Medicine during the first quarter valued at $53,207,000. Wellington Management Group LLP boosted its stake in Disc Medicine by 67.9% in the 1st quarter. Wellington Management Group LLP now owns 2,343,499 shares of the company's stock worth $116,331,000 after purchasing an additional 948,094 shares in the last quarter. Vanguard Group Inc. boosted its stake in Disc Medicine by 22.2% in the 1st quarter. Vanguard Group Inc. now owns 1,305,046 shares of the company's stock worth $64,782,000 after purchasing an additional 236,800 shares in the last quarter. Finally, Sio Capital Management LLC boosted its stake in Disc Medicine by 287.4% in the 2nd quarter. Sio Capital Management LLC now owns 284,787 shares of the company's stock worth $15,082,000 after purchasing an additional 211,276 shares in the last quarter. Institutional investors own 83.70% of the company's stock.

About Disc Medicine

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.